precision oncology

By Dave Muoio 02:52 pm July 29, 2020
Sema4, a Mount Sinai spinout developing health-data-analytics platforms, has raised $121 million in Series C funding. BlackRock led the oversubscribed round, which also saw participation from new investors Deerfield Management Company and Moore Strategic Ventures, and also old backers Blackstone, Section 32, Oak HC/FT, Decheng and Connecticut Innovations. With this round, coming less than a year...
By Dean Koh 01:41 am January 6, 2020
Cancer has been the leading cause of death in Japan since 1981 and this is compounded by the fact that the country has a hyper-aging society, which means that Japan will face a substantial increase in the number of elderly cancer patients, according to a review article by Matsuda and Saika published in the Annals of Cancer Epidemiology in 2018. Prof Yasushi Goto of the National Cancer Center...
By Dave Muoio 12:00 pm April 9, 2019
Concerto HealthAI, the maker of a clinical insight generation platform that employs real-world data in its analyses, is racking up the pharma partnerships as of late. Just weeks after the artificial intelligence company agreed to a multi-year deal with Bristol-Myers Squibb, Concerto announced this morning a similar project with Pfizer that will support the latter’s research on precision oncology...

Inside the wearable device, the blood pump sits in the upper left corner while the heparin injector runs the length of the near side of the box. The green circuit boards control the blood pump, heparin injector and provide display data. Photo Credit: Tae Hyun Kim

By Dave Muoio 12:19 pm April 1, 2019
In an open Nature Communications paper published today, researchers from the University of Michigan described a prototype wearable device that could continuously collect bloodborne cancer cells often used as a biomarker for treatment. Currently, blood draws are required to identify and examine circulating tumor cells (CTCs), and are often limited by inconsistent CTC counts as well as the health...

Photo: Dr. James Creeden, Global Medical Director of Foundation Medicine​. Credit: Foundation Medicine.

By Dean Koh 10:30 pm January 10, 2019
Launched in 2010 with a $25 million Series A financing led by Third Rock Ventures, Foundation Medicine released its first commercial assay called FoundationOne in 2012. The company develops, manufactures, and sells genomic profiling assays based on next-generation sequencing technology for solid tumours, hematologic malignancies, and sarcomas. In December 2017, the company’s assay FoundationOne...

Credit: Foundation Medicine

By Dean Koh 02:46 am November 29, 2018
Roche announced last week the launch of FoundationOne CDx, Foundation Medicine’s comprehensive companion diagnostic test for personalised cancer care in Singapore. According to the official media release, FoundationOne CDx supports clinicians in their decision-making by providing a clear, in-depth report that describes the unique genomic profile of a patient’s tumour as well as associated,...
By Dave Muoio 06:03 am July 19, 2018
The Department of Veterans Affairs and IBM Watson Health have announced a one-year extension to an ongoing public-private partnership applying the AI company’s technology to genomic data for cancer therapy. The precision oncology collaboration has so far assisted the treatment of more than 2,700 veterans, according to a statement, although the original agreement in 2016 had proposed the lofty...